Although GFAP immunoreactivity is decreased with increasing astrocytoma grade [17], it is also known that a complete lack of all GFAP-isoforms, as in the GFAP−/− mice, is not sufficient to increase tumorigenicity [33]. This evidence concerns the gene GFAP and astrocytoma (excluding glioblastoma).